Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

ABSTRACT: The identification of lung tumor-initiating cells and associated markers may be useful for optimization of therapeutic approaches and for predictive and prognostic information in lung cancer patients. CD133, a surface glycoprotein linked to organ-specific stem cells, was described as a marker of cancer-initiating cells in different tumor types. Here, we report that a CD133+, epithelial-specific antigen-positive (CD133+ESA+) population is increased in primary nonsmall cell lung cancer (NSCLC) compared with normal lung tissue and has higher tumorigenic potential in SCID mice and expression of genes involved in stemness, adhesion, motility, and drug efflux than the CD133(-) counterpart. Cisplatin treatment of lung cancer cells in vitro resulted in enrichment of CD133+ fraction both after acut

SUBMITTER: Bertolini G 

PROVIDER: S-EPMC2741477 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature